Cargando…

Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease

BACKGROUND: Nonadherence to biologic therapy in inflammatory bowel disease (IBD) is associated with risk of relapse, immunogenicity, and disease complications. Significant nonadherence prevalence is reported with tumor necrosis factor (TNF) antagonists but the risk of nonadherence with newer biologi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kumar, Anand, Kim, Emilie S, Kozan, Philip, Jacob, Vinita, Longman, Randy S, Scherl, Ellen J, Battat, Robert J, Lukin, Dana J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Observations and Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802380/ https://www.ncbi.nlm.nih.gov/pubmed/36777752 http://dx.doi.org/10.1093/crocol/otaa074

Ejemplares similares

The Impact of Confounders on Symptom–Endoscopic Discordances in Crohn’s Disease
por: Rajan, Anjana, et al.
Publicado: (2023)

Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
por: Newman, Kira L., et al.
Publicado: (2023)

Defining the phenotype, pathogenesis and treatment of Crohn’s disease associated spondyloarthritis
por: Kumar, Anand, et al.
Publicado: (2020)

Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS-CoV-2 Vaccination
por: Charilaou, Paris, et al.
Publicado: (2022)

Su1487: IMPACT OF INFLAMMATORY BOWEL DISEASE THERAPIES ON DURABILITY OF HUMORAL RESPONSE TO SARS COV-2 VACCINATION
por: Charilaou, Paris, et al.
Publicado: (2022)

Prevalence and factors associated with vitamin C deficiency in inflammatory bowel disease
por: Gordon, Benjamin Langan, et al.
Publicado: (2022)

Favorable Outcomes Combining Vedolizumab With Other Biologics or Tofacitinib for Treatment of Inflammatory Bowel Disease
por: Llano, Ernesto M, et al.
Publicado: (2021)

Higher Adalimumab Trough Levels Are Associated with Histologic Remission and Mucosal Healing in Inflammatory Bowel Disease
por: Wong, Rochelle, et al.
Publicado: (2023)

No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD
por: Lukin, Dana J., et al.
Publicado: (2021)

Serum Ustekinumab Concentrations Are Associated With Remission in Crohn’s Disease Defined by a Serum-Based Endoscopic Healing Index
por: Walshe, Margaret, et al.
Publicado: (2021)

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
por: Shim, Hang Hock, et al.
Publicado: (2018)

Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease
por: Lukin, Dana J., et al.
Publicado: (2020)

Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients
por: Breidert, Matthias, et al.
Publicado: (2020)

Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Comparing Patient-Reported Outcomes Among Anti-TNF Experienced Patients With Ulcerative Colitis Initiating Vedolizumab Versus Tofacitinib
por: Kappelman, Michael D, et al.
Publicado: (2023)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017)

Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn’s Disease Patients
por: Gebeyehu, Gerum Gashaw, et al.
Publicado: (2022)

The Early Experience With Vedolizumab in the United States
por: Kochar, Bharati, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
por: Holko, Przemysław, et al.
Publicado: (2018)

Adalimumab/ustekinumab/vedolizumab: COVID-19 infection: 7 case reports
Publicado: (2022)

Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
por: Gisbert, Javier P., et al.
Publicado: (2023)

Ustekinumab Exposure in Pregnant Women From Inflammatory Bowel Disease Clinical Trials: Pregnancy Outcomes Through Up To 5 Years in Crohn’s Disease and 2 Years in Ulcerative Colitis
por: Abraham, Bincy P, et al.
Publicado: (2022)

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
por: Choi, Myeong Geun, et al.
Publicado: (2022)

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
por: Lutz, Megan, et al.
Publicado: (2023)

Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
por: Restellini, Sophie, et al.
Publicado: (2021)

Vedolizumab Experience in Children and Adolescents With Inflammatory Bowel Disease: A Multicenter Observational Study
por: Hajjat, Temara M, et al.
Publicado: (2021)

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Cassandra, Rayer, et al.
Publicado: (2022)

Vedolizumab use after failure of TNF-α antagonists in children and adolescents with inflammatory bowel disease
por: Schneider, Anna-Maria, et al.
Publicado: (2018)

Effectiveness and Durability of Ustekinumab Therapy With or Without Immunomodulators for Ulcerative Colitis Patients in Japan
por: Aoki, Yasuhiro, et al.
Publicado: (2022)

Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study
por: Rayer, Cassandra, et al.
Publicado: (2023)

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease
por: Bohm, Matthew, et al.
Publicado: (2020)

Evaluation of the Optimal Position for Vedolizumab in the Japanese Treatment Paradigm for Ulcerative Colitis Using Markov Modeling
por: Uda, Akihito, et al.
Publicado: (2020)

CT or MR Enterography to Assess Response During Vedolizumab Therapy for Small Bowel Crohn’s Disease
por: Kwapisz, Lukasz, et al.
Publicado: (2022)

The Immunogenicity of the Influenza, Pneumococcal, and Hepatitis B Vaccines in Patients With Inflammatory Bowel Disease Treated With Vedolizumab
por: Harrington, Jill E, et al.
Publicado: (2020)

Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States
por: Hong, Simon J, et al.
Publicado: (2021)

Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study
por: Mitrova, Katarina, et al.
Publicado: (2021)

Long-Term Clinical Effectiveness of Ustekinumab in Patients With Crohn’s Disease: A Retrospective Cohort Study
por: Ito, Takahiro, et al.
Publicado: (2020)

Real-World Experience With Acute Infusion Reactions to Ustekinumab at 2 Large Tertiary Care Centers
por: Spencer, Elizabeth A, et al.
Publicado: (2020)

Vedolizumab in Mild-to-Moderate Crohn’s Disease Patients Naïve to Biological Therapy: A Multicentric Observational Study
por: Dotti, Adriana Zanoni, et al.
Publicado: (2023)

Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study
por: Burgevin, Alice, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8muv9ldbul8d0uuv1p7o7m7jl6